Mohammad Sharifi Sarasyabi

Mohammad Sharifi Sarasyabi

Auto-generated profile, based on publicly available information

Mohammad Sharifi Sarasyabi

Medical Informatics Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 November 2022 in Pediatric Pulmonology
Verified
Journal Article
Closed access
YPYasamin Parvar
Yasamin Parvar
MSMohammad Sharifi Sarasyabi
Mohammad Sharifi Sarasyabi
MMMohammad Ashkan Moslehi
Mohammad Ashkan Moslehi
KPKostas N. Priftis
Kostas N. Priftis
RCRenato Cutrera
Renato Cutrera
NFNader Fasseeh
Nader Fasseeh

27 March 2023 in European Journal of Medical Research
Verified
Journal Article
Open access
PDF file
MRMasoud Rezaei
Masoud Rezaei
MFMahsa Faramarzpour
Mahsa Faramarzpour
PSParnian Shobeiri
Parnian Shobeiri
HSHoma Seyedmirzaei
Homa Seyedmirzaei
MSMohammad Sharifi Sarasyabi
Mohammad Sharifi Sarasyabi
SDShahriar Dabiri
Shahriar Dabiri
Glaucoma is a chronic neurodegenerative process of the optic nerve that is the leading cause of blindness worldwide, and early diagnosis of the disease could greatly affect patients’ prognoses. The pathophysiology of glaucoma is complicated by a combination of genetic and epigenetic factors. Deciphering the early diagnostic biomarkers in glaucoma could attenuate the disease's global burden and help us understand the exact mechanisms involved in glaucoma. The microRNAs are members of a larger family of non-coding RNAs that play an essential role in the epigenetic basis of glaucoma. A systematic study and meta-analysis of diagnostic microRNAs in glaucoma, jointly with network analysis of target genes, were carried out on published papers assessing differentially expressed microRNAs in human subjects. In total, 321 articles were found, and, after screening, six studies were eligible for further analysis. 52 differentially expressed microRNAs were found, of which 28 and 24 were up-regulated and down-regulated, respectively. Only 12 microRNAs were qualified for meta-analysis, with overall sensitivity and specificity of 80% and 74%, respectively. Then, using network analysis, it became apparent that the VEGF-A, AKT1, CXCL12, and HRAS genes were the most important targets for the microRNAs. Perturbations in WNT signaling, protein transport, and extracellular matrix organization pathways were discovered to be important in the etiology of glaucoma using the community detection approach. This study tries to uncover the promising microRNAs and their target genes that govern the epigenetics of glaucoma.

6 October 2021 in Lasers in Medical Science
Verified
Journal Article
Closed access
PDF file
NANajmeh Ahramiyanpour
Najmeh Ahramiyanpour
ZAZahra Akbari
Zahra Akbari
MSMohammad Sharifi Sarasyabi
Mohammad Sharifi Sarasyabi
MAMahin Aflatoonian
Mahin Aflatoonian
NSNasrin Saki
Nasrin Saki
MSMohammad Shafie’ei
Mohammad Shafie’ei

5 January 2026 in Advances in Rheumatology
Verified
Journal Article
Open access
PDF file
MSMohammad Sharifi Sarasyabi
Mohammad Sharifi Sarasyabi
NSNiloofar Seighali
Niloofar Seighali
MAMaryam Abdolmaleki
Maryam Abdolmaleki
PSParnian Shobeiri
Parnian Shobeiri
MMMohammad R. Movahed
Mohammad R. Movahed
SMSaba Maleki
Saba Maleki
Psoriasis is a chronic inflammatory skin condition affecting 0.1–1.5% of the global population. The condition is linked to impaired quality of life a

3 July 2026 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
BMBabak Mansourian
Babak Mansourian
TSTarannom Sadegh
Tarannom Sadegh
AHAmirhossein Habibzadeh
Amirhossein Habibzadeh
SHSogol Hajifathali
Sogol Hajifathali
ADAsal Khalili Dehkordi
Asal Khalili Dehkordi
KDKhashayar Danandeh
Khashayar Danandeh
Introduction: Gallbladder and biliary tract cancer (GBTC) is a rare but aggressive malignancy with poor survival outcomes, mainly due to late-stage diagnosis and limited treatment options. Despite prominent global disparities in incidence and outcomes, comprehensive data on the GBTC burden in the Middle East and North Africa (MENA) region remain scarce. Materials and methods: We used Global Burden of Disease (GBD) 2021 data. We retrieved incidence, deaths, and DALYs, including crude and age-standardized rates per 100 000, with 95% uncertainty intervals for 21 MENA countries, the MENA region, and globally, stratified by year (1990–2021), sex, and age group. Results: In the MENA region, the age-standardized incidence rate (ASIR) remained at 1.4 per 100 000 in both 1990 and 2021 (−0.2% change), while globally it declined from 2.89 to 2.56 (−11.5%; 95% UI: −21.9 to −3.4). The age-standardized death rate (ASDR) decreased from 1.50 to 1.37 (−9.0%) in MENA versus 2.69 to 2.04 (−24.1%; 95% UI: −33.2 to −16.9) globally. The age-standardized DALY rate fell from 34.26 to 29.82 (−13.0%) in MENA and from 58.58 to 43.20 (−26.2%; 95% UI: −35.5 to −18.4) globally. Across years, females had higher age-standardized rates than males, rates increased with age, and the peak DALY rate shifted from 80–84 (1990) to 85–89 (2021). Conclusions: While the burden of GBTC has decreased in the MENA region and has consistently remained lower than the global average, there is considerable heterogeneity across countries in the region that warrants the attention of policymakers, particularly in countries with a higher burden of GBTC, such as Libya and the United Arab Emirates, and in countries with an increasing burden, such as Iran.

16 April 2026 in Journal of Medical Mycology
Verified
Journal Article
Closed access
MAMehraneh Movahedi Aliabadi
Mehraneh Movahedi Aliabadi
MSMohammad Sharifi Sarasyabi
Mohammad Sharifi Sarasyabi
RAReyhaneh Asoudeh
Reyhaneh Asoudeh
KMKeihan Mostafavi
Keihan Mostafavi
MEMaryam Emadzadeh
Maryam Emadzadeh
Hossein ZarrinfarHossein Zarrinfar
Hossein Zarrinfar